Name: | tiotropium |
---|---|
PubChem Compound ID: | 10649780 |
Molecular formula: | C32H35NO4Si |
Molecular weight: | 525.71 g/mol |
Name: | tiotropium |
---|---|
Name (isomeric): | DB01409 |
Drug Type: | small molecule |
Synonyms: |
Tiotropium bromide
|
Brand: | Spiriva |
Category: | Muscarinic Antagonists, Parasympatholytics, Cholinergic Antagonists, Anticholinergic Agents, Bronchodilator Agents |
CAS number: | 186691-13-4 |
Indication: | Used in the management of chronic obstructive pulmonary disease (COPD). |
---|---|
Pharmacology: |
Tiotropium is a long–acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3–receptors at the smooth muscle leading to bronchodilation. The competitive and reversible nature ...
show more » |
Mechanism of Action: |
Tiotropium is a muscarinic receptor antagonist, often referred to as an antimuscarinic or anticholinergic agent. Although it does not display selectivity for specific muscarinic receptors, on topical application it acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation, thus producing a bronchodilatory eff...
show more » |
Absorption: | Bioavailability is 19.5% following administration by inhalation. Oral solutions of tiotropium have an absolute bioavailability of 2-3%. |
Protein binding: | 72% bound to plasma proteins. |
Biotransformation: | The extent of biotransformation appears to be small. This is evident from a urinary excretion of 74% of unchanged substance after an intravenous dose to young healthy volunteers. Tiotropium, an ester, is nonenzymatically cleaved to the alcohol N–methylscopine and dithienylglycolic acid, neither of which bind to muscarinic receptors. In vitro experiments with human liver microsomes and human hepatocytes suggest that a fraction of the administered dose (74% of an intravenous dose is excreted unchanged in the urine, leaving 25% for metabolism) is metabolized by cytochrome P450–dependent oxidation and subsequent glutathione conjugation to a variety of Phase II metabolites. Via inhibition studies, it is evident that CYP450 2D6 and 3A4 are involved in the metabolic pathway that is responsible for the elimination of a small part of the administered dose. |
Route of elimination: | Intravenously administered tiotropium was mainly excreted unchanged in urine (74%). After dry powder inhalation, urinary excretion was 14% of the dose, the remainder being mainly non-absorbed drug in the gut which was eliminated via the feces. |
Half Life: | 5-6 days |
Clearance: | 880 mL/min [young healthy volunteers receiving IV administration] Renal cl=326 mL/min [COPD patients (<58 years)] Renal cl=163 mL/min [COPD patients (>70 years)] |
Toxicity: | No mortality was observed at inhalation tiotropium doses up to 32.4 mg/kg in mice, 267.7 mg/kg in rats, and 0.6 mg/kg in dogs. These doses correspond to 7,300, 120,000, and 850 times the recommended human daily dose on a mg/m2 basis, respectively. |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|